

## **Lion Biotechnologies to Participate in Upcoming Investor Conferences**

May 19, 2015 12:11 PM ET

LOS ANGELES, May 19, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) today announced that president and CEO Elma Hawkins, PhD, will participate in the following upcoming investor conferences:

### **Piper Jaffray GenomeRx Symposium**

Date: Wednesday – Thursday, May 20-21, 2015

Panels: CAR-T: Engineering Lethal Lymphocytes, May 20, 10:25 am; Cellular Therapies: Toolkits and Platforms, May 20, 11:50 am

Location: The New York Palace Hotel, New York

### **Sachs Immuno-Oncology BD&L and Investment Forum**

Date: Friday, May 29, 2015

Panel: Immunotherapeutics: ADCs and Combination Therapies – BD&L, May 29, 10:20 am

Corporate Presentation: May 29, 1:30 pm

Location: Hyatt Chicago Magnificent Mile, Chicago

### **Jefferies 2015 Healthcare Conference**

Date: Monday – Thursday, June 1-4, 2015

Corporate Presentation: June 1, 10:00 am

Location: Grand Hyatt, New York

## **About Lion Biotechnologies**

Lion Biotechnologies, Inc. is engaged in the development of T cells and engineered T cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse, autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with Stage 4 metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. For more information, please visit <http://www.lionbio.com>.

## **Forward Looking Statements**

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Relations  
The Trout Group  
Elizabeth Broder  
646-378-2945  
ebroder@troutgroup.com

Source: Lion Biotechnologies, Inc.

Released May 19, 2015